Your browser doesn't support javascript.
loading
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Tsaur, Grigory; Popov, Alexander; Riger, Tatiana; Kustanovich, Anatoly; Solodovnikov, Alexander; Shorikov, Egor; Demina, Anna; Verzhbitskaya, Tatiana; Streneva, Olga; Makarova, Olga; Lapotentova, Elena; Aleinikova, Olga; Miakova, Natalia; Boichenko, Elmira; Kondratchik, Konstantin; Ponomareva, Natalia; Karachunskiy, Alexander; Roumiantsev, Alexander; Fechina, Larisa.
Afiliação
  • Tsaur G; Regional Children's Hospital, Ekaterinburg, Russian Federation.
  • Popov A; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
  • Riger T; Ural State Medical University, Ekaterinburg, Russian Federation.
  • Kustanovich A; National Research and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
  • Solodovnikov A; Regional Children's Hospital, Ekaterinburg, Russian Federation.
  • Shorikov E; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
  • Demina A; The Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, Israel.
  • Verzhbitskaya T; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
  • Streneva O; Ural State Medical University, Ekaterinburg, Russian Federation.
  • Makarova O; PET-Technology Center of Nuclear Medicine, Ekaterinburg, Russian Federation.
  • Lapotentova E; Regional Children's Hospital, Ekaterinburg, Russian Federation.
  • Aleinikova O; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
  • Miakova N; Regional Children's Hospital, Ekaterinburg, Russian Federation.
  • Boichenko E; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
  • Kondratchik K; Regional Children's Hospital, Ekaterinburg, Russian Federation.
  • Ponomareva N; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation.
  • Karachunskiy A; Regional Children's Hospital, Ekaterinburg, Russian Federation.
  • Roumiantsev A; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
  • Fechina L; Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
Br J Haematol ; 193(6): 1151-1156, 2021 06.
Article em En | MEDLINE | ID: mdl-33583020
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão Oncogênica / Histona-Lisina N-Metiltransferase / Proteína de Leucina Linfoide-Mieloide Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Infant / Male / Newborn Idioma: En Revista: Br J Haematol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão Oncogênica / Histona-Lisina N-Metiltransferase / Proteína de Leucina Linfoide-Mieloide Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans / Infant / Male / Newborn Idioma: En Revista: Br J Haematol Ano de publicação: 2021 Tipo de documento: Article